Search results for "polycystic ovary syndrome."

showing 10 items of 62 documents

Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.

2013

Background Obesity is known to underlie, at least partially, dyslipidemia in polycystic ovary syndrome (PCOS), but it is unclear whether PCOS status per se increases the risk of alterations of lipoprotein subfractions, which differ in size and atherogenic potential. Our objective was to evaluate whether PCOS influences lipoprotein profile and LDL and HDL subfractions and to study the impact of obesity on these parameters. Materials and methods This was a case–control study conducted in an academic medical centre. The study population consisted of 54 women of fertile age with PCOS and 60 controls adjusted for age and BMI. Biochemical lipid profile and LDL and HDL lipoprotein subfractions (me…

AdultVery low-density lipoproteinmedicine.medical_specialtyendocrine system diseasesClinical BiochemistryBiochemistryBody Mass Indexchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansObesityDyslipidemiasmedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral MedicineAtherosclerosismedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologychemistryCase-Control StudiesFemalelipids (amino acids peptides and proteins)Lipid profilebusinessBody mass indexDyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

A 20-year follow-up of young women with polycystic ovary syndrome.

2012

OBJECTIVE: To determine whether hormonal, metabolic, and anthropomorphic parameters change over 20 years in women with polycystic ovary syndrome (PCOS). METHODS: One hundred ninety-three women with PCOS, aged 20–25 years, were diagnosed according to Rotterdam criteria, divided into four phenotypes (A–D), and followed at 5-year intervals for 20 years. Androgens, gonadotropins, insulin, glucose, body mass index, waist circumference, and ovarian volume were measured. RESULTS: At diagnosis, 57% had classic features (phenotype A), 9% had classic features without ovarian findings (phenotype B), 26% had the ovulatory phenotype (C), and 7% were nonhyperandrogenic (D). After 10 years, androgens decr…

Adultendocrine system diseasesPhysiologySettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultInsulin resistanceOvarian functionmedicineHumansInsulinTestosteroneYoung adultInsulin bloodbusiness.industryOvaryFollow up studiesObstetrics and GynecologyDehydroepiandrosteroneOrgan SizeLuteinizing HormoneMiddle Agedmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsPolycystic Ovary Syndrome Ovarian function Ovarian aging Androgens Insulin resistance waist circumferencePhenotypeFemaleFollicle Stimulating HormoneInsulin ResistanceWaist CircumferencebusinessBody mass indexHormoneAnovulationFollow-Up StudiesPolycystic Ovary SyndromeObstetrics and gynecology
researchProduct

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.

2006

Abstract Context: An altered lipid profile is common in polycystic ovary syndrome (PCOS) and is usually characterized by increased triglycerides and low high-density lipoprotein (HDL)-cholesterol levels. In the general population, these alterations are often associated with the increase of small low-density lipoproteins (LDLs) in the so-called “atherogenic lipoprotein phenotype” (ALP) that determines a further increase of cardiovascular risk. In this study, we evaluated the presence of ALP in the plasma of women with PCOS. Setting: Measurements and analysis of LDL size were performed at the Clinic of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich. PCOS patients…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationClinical nutritionBiologyBiochemistryAnovulationEndocrinologyDiabetes mellitusInternal medicinemedicineHumansInsulinParticle SizeeducationTriglyceridesAtherogenic lipoprotein low-density lipoproteins polycystic ovary syndromeeducation.field_of_studymedicine.diagnostic_testBiochemistry (medical)HyperandrogenismCholesterol HDLnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryLipoproteins LDLEndocrinologyPhenotypelipids (amino acids peptides and proteins)FemaleLipid profileLipoproteinPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis

2019

This study aimed to evaluate the prevalence (P)/hazard ratio (HR) of cardiovascular (CV) events among reproductive age and menopausal age women with polycystic ovary syndrome (PCOS) in comparison with healthy controls. PubMed, Scopus, ScienceDirect, Web of science, and Google scholar were searched for retrieving observational studies published up to April 2018 investigating CV events in patients with PCOS. The primary outcomes were a composite outcome of CV events [including coronary arterial disease (CAD), cardiovascular disease (CVD), myocardial infarction (MI), angina, heart failure, and ischemic heart disease] and mortality due to CV events; secondary outcomes were specific CVD events, …

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationMyocardial InfarctionMyocardial Ischemia030209 endocrinology & metabolismCoronary Artery DiseaseAngina PectorisAngina03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinePrevalencemedicineHumansMyocardial infarctionRisk factoreducationAgedProportional Hazards ModelsHeart Failureeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryPolycystic ovary syndrome (PCOS)Hazard ratioObstetrics and GynecologyMiddle Agedmedicine.diseasePolycystic ovaryStrokeCerebrovascular DisordersCardiovascular DiseasesCase-Control StudiesFemalebusinessPolycystic Ovary SyndromeCohort studyGynecological Endocrinology
researchProduct

Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Tr…

2005

Abstract Context: Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients. Objective: The goal of this study was to compare the effectiveness of metformin and CC administration as a first-line treatment in anovulatory women with PCOS. Design: We describe a prospective parallel randomized, double-blind, double-dummy controlled clinical trial. Setting: The study was conducted at the University “Magna Graecia” of Catanzaro, Catanzaro, Italy. Patients: One hundred nonobese primary infertile anovulatory women with PC…

Adultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryWEIGHT-LOSSIMPROVEMENTContext (language use)PLACEBO-CONTROLLED TRIALPlaceboTHERAPYBiochemistrylaw.inventionAnovulationEndocrinologyDouble-Blind MethodOvulation InductionRandomized controlled trialClomifenelawinsulin resistanceInternal medicinePCOSmedicineHumansCRITERIAclomipheneProspective StudiesPolycystic ovary syndromeGynecologybusiness.industryBiochemistry (medical)medicine.diseasePolycystic ovarymetformineMetforminPREGNANCYEndocrinologyPCOS; metformine; clomipheneovulationFemaleOvulation inductionGLUCOSE-TOLERANCEclomifenemetforminbusinessOBESE WOMENAnovulationmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients

2015

Abstract Objective We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects. Methods The study population consisted of 40 reproductive-age women with PCOS, who underwent treatment with metformin during a 12-week period, and their corresponding matched controls (n = 44). We evaluated endocrinological parameters, adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)) in serum. In addition, interactions between human umbili…

Adultmedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndotheliumType 2 diabetesProinflammatory cytokineYoung AdultInsulin resistanceInternal medicineCell AdhesionHuman Umbilical Vein Endothelial CellsLeukocytesmedicineHumansLeukocyte RollingEndothelium Leukocyte Metformin Mitochondria PCOS Type 2 diabetesCells CulturedCell adhesion moleculebusiness.industryEndothelial Cellsnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryCoculture TechniquesMetforminMetforminEndothelial stem cellTreatment Outcomemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2SpainCytokinesFemaleInflammation MediatorsCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersPolycystic Ovary Syndromemedicine.drugAtherosclerosis
researchProduct

Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in Southern Italy than in USA and the influence of criteria for the diagnosi…

2005

Objective: Metabolic syndrome (MBS) is a common disorder and is thought to be extremely prevalent in polycystic ovary syndrome (PCOS). In the USA the prevalence of MBS in PCOS has been reported to be as high as 43–46% using Adult Treatment Panel III (ATP-III) criteria. Because of differences in diet, lifestyle and genetic factors, we postulated that the prevalence of MBS might not be as high in Italian women. This study sought to determine the prevalence of MBS in Italian women using both the ATP-III and the World Health Organization (WHO) criteria and to determine whether the prevalence is influenced by the way in which PCOS is diagnosed. Design: Assessment of the prevalence of MBS in 282 …

Adultmedicine.medical_specialtyanimal structuresAdolescentEndocrinology Diabetes and MetabolismPopulationPrevalenceAnovulationEndocrinologyInsulin resistanceInternal medicinemedicinePrevalenceHumanseducationHypertriglyceridemiaeducation.field_of_studybusiness.industryPolycystic ovary syndrome (PCOS)HyperandrogenismGeneral Medicinemedicine.diseasePolycystic ovaryMetabolic syndromeUnited StatesEndocrinologyItalyFemaleMetabolic syndromebusinessPolycystic Ovary Syndrome
researchProduct